SEC Filing Analysis: TScan Therapeutics, Inc.

Executive Summary

• Trading Significance: High
• Key Takeaway: Readout Capital, LP and affiliated entities filed an initial Schedule 13G reporting a 5.4% beneficial stake (3,453,388 shares).
• Market Impact: Neutral to Positive institutional accumulation signal for a micro-cap life sciences issuer.

Company Information

Field	Value
Company	TScan Therapeutics, Inc.
Ticker Symbol	Not Disclosed in Filing
CIK	0001783328
Industry	Biological Products (No Diagnostic Substances) [2836]

Insider Information

Field	Value
Name	Readout Capital, LP / Matthew Smith
CIK	0002063423
Title/Position	Investment Manager / General Partner
Relationship	5% Beneficial Owner

Transaction Details

Field	Value
Form Type	SCHEDULE 13G
Event Date	2026/09/21
Security Type	Voting Common Stock, $0.0001 par value per share
Aggregate Shares Owned	3,453,388
Reported Ownership %	5.4%
Voting Power	Shared: 3,453,388 / Sole: 0
Dispositive Power	Shared: 3,453,388 / Sole: 0
Ownership Nature	Indirect (via Readout Capital Master Fund, LP and Sub-Advised Funds)

Financial Impact Assessment

Transaction Materiality

Metric	Value
Shares Owned	3,453,388
Total Shares Outstanding	65,350,000
Ownership % of Current Float	5.28% (5.4% per 10-Q benchmark)
Market Capitalization Tier	Micro-Cap (~$20M)
Materiality Assessment	Highly Significant

Impact Evaluation

• Market Cap Context: For an issuer with a market capitalization of roughly $20M, accumulating 3.45M shares represents substantial absorption of the public float.
• Ownership Concentration: The reporting persons control 5.28% of total common shares outstanding, qualifying them as a major institutional stakeholder under SEC Rule 13d-1(c).
• Dilution & Strategy: Because this filing reflects secondary market accumulation under Schedule 13G, there is no share dilution; holdings are designated strictly passive without intent to influence company control.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral to Positive
• Reasoning: Crossings of the 5% threshold by institutional funds often reflect conviction, reducing tradeable float and validating the investment thesis for small-cap biotechs.

Volume & Sentiment

• Expected Volume Impact: Modest short-term liquidity tightening given that over 5% of shares are now sequestered in institutional investment vehicles.
• Sentiment Indicator: Neutral

Investment Insights

Positive Market Indicators

• Institutional fund establishment of a significant 5%+ stake.
• Micro-cap ownership validation by specialized healthcare/life-sciences capital managers.

Risk Factors

• Passive status (Rule 13d-1(c)) indicates no board seats or activist governance involvement.
• Institutional funds may liquidate positions in open-market transactions without advance public notice.

Key Takeaways

1. Readout Capital, LP, Readout Capital GP, LLC, and Managing Member Matthew Smith jointly report beneficial ownership of 3,453,388 common shares.
2. The aggregate position represents 5.4% based on August 2026 10-Q share counts and 5.28% against current outstanding shares.
3. The filing certifies passive intent with shared voting and dispositive control.